837364-57-5
基本信息
AG-24322
AG-024322
AG024322
AG-024322
5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-3-Pyridinemethanamine
3-Pyridinemethanamine, 5-[3-(5,7-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4-methyl-
N-((5-((19E)-3-(4,6-DIFLUORO-2H-BENZO[D]IMIDAZOL-2-YLIDENE)-2,3-DIHYDRO-1H-INDAZOL-5-YL)-4-METHYLPYRIDIN-3-YL)METHYL)ETHANAMINE
物理化学性质
| 沸点 | 668.4±65.0 °C(Predicted) |
| 密度 | 1.361±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C储存 |
| 酸度系数(pKa) | 7.84±0.30(Predicted) |
| 形态 | Solid |
| 颜色 | White to off-white |
CS-1092价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-15491 | AG-024322 | 837364-57-5 | 1 mg | 2400元 |
| 2025/12/22 | HY-15491 | CS-1092 AG-024322 | 837364-57-5 | 5mg | 6000元 |
| 2025/12/22 | HY-15491 | CS-1092 AG-024322 | 837364-57-5 | 10 mM * 1 mLin DMSO | 6600元 |
常见问题列表
|
COX-1 2.3 nM (Ki) |
COX-2 3 nM (Ki) |
COX-4 2.9 nM (Ki) |
AG-024322 (0.1-30 μM; 24 hours) is less toxic at concentrations below 3 µM, the viability of human PBMCs as measured by ATP content with a TC 50 value of 1.4 µM for human PBMCs.AG-024322 (0-120 nM) exhibits growth inhibition effects on HCT-116 cells. It is slightly less potent in the functional cellular assay with an IC 50 of 120 nM.
AG-024322 (intravenous infusion; 2, 6, and 10 mg/kg; 5 days) exhibits no-adverse-effect at 2 mg/kg with mean plasma AUC (0-24.5) of 2.11 g.h/mL. At 6 mg/kg produces pancytic bone marrow hypocellularity, lymphoid depletion. And vascular injury at the injection site renal tubular degeneration occurs at 10 mg/kg.AG-024322 (20 mg/kg) inhibits the growth of established human tumor xenografts of different origins with tumor growth inhibition (TGI) ranging from 32% to 86.4%.It also exhibits anti-tumor effects as a dose-pdependent manner.AG-024322 (20 mg/kg) causes a 65% TGI in the MV522 tumor model. It results a 52% TGI at 1/2 of the maximum tolerated dose (MTD) and only slight anti-tumor activity at 1/4 of the MTD.
| Animal Model: | Male and female cynomolgus monkeys |
| Dosage: | 2, 6, and 10 mg/kg (Toxicity analysis) |
| Administration: | Intravenous infusion; 5 days |
| Result: | Resulted in dose-dependent pancytic bone marrow hypocellularity and lymphoid depletion in lymph nodes, spleen, and/or thymus at >6 mg/kg. |